Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272872 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13521346 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13522947 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13523196 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13522767 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13521334 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL8274121 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13521339 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL8274537 | 0.94 | CTSB (0.58) | CTSBPPP3CBCYP3A4ABCC1ABCC2 | |
| SCHEMBL13521335 | 0.94 | CTSB (0.61) | CTSBPPP3CBCYP3A4ABCC1ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778702-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2316839-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | CTSB 1150/4885PPP3CB 292/4885CYP3A4 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.